Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Inks Pharmacogenetics Services Deal with Schering-Plough Canada

NEW YORK (GenomeWeb News) - Warnex Medical Laboratories will develop several new pharmacogenetic assays for Schering-Plough Canada, Warnex said last week.
 
Under the agreement, Warnex said it will supply pharmacogenetic and molecular biology services for Schering-Plough’s clinical trials for cancer and infectious disease therapeutics.
 
Warnex said the company is using its services to identify patients who are more likely to respond to a treatment or who are less likely to have an adverse event.
 
Financial terms of the agreement were not released.